Image showing individual and combined scans
Credit: Evis Sala
A new advanced computing technique using routine medical scans to enable doctors to take fewer, more accurate tumour biopsies, has been developed by cancer researchers at the University of Cambridge. This is an important step towards precision tissue sampling for cancer patients to help select the best treatment. In future the technique could even replace clinical biopsies with ‘virtual biopsies’, sparing patients invasive procedures.
This study provides an important milestone towards precision tissue sampling. We are truly pushing the boundaries in translating cutting edge research to routine clinical care
The research published in European Radiology shows that combining computed tomography (CT) scans with ultrasound images creates a visual guide for doctors to ensure they sample the full complexity of a tumour with fewer targeted biopsies.
Capturing the patchwork of different types of cancer cell within a tumour – known as tumour heterogeneity – is critical for selecting the best treatment because genetically-different cells may respond differently to treatment.
Most cancer patients undergo one or several biopsies to confirm diagnosis and plan their treatment. But because this is an invasive clinical procedure, there is an urgent need to reduce the number of biopsies taken and to make sure biopsies accurately sample the genetically-different cells in the tumour, particularly for ovarian cancer patients.
High grade serous ovarian (HGSO) cancer, the most common type of ovarian cancer, is referred to as a ‘silent killer’ because early symptoms can be difficult to pick up. By the time the cancer is diagnosed, it is often at an advanced stage, and survival rates have not changed much over the last 20 years.
But late diagnosis isn’t the only problem. HGSO tumours tend to have a high level of tumour heterogeneity and patients with more genetically-different patches of cancer cells tend to have a poorer response to treatment.
Professor Evis Sala from the Department of Radiology, co-lead CRUK Cambridge Centre Advanced Cancer Imaging Programme, leads a multi-disciplinary team of radiologists, physicists, oncologists and computational scientists using innovative computing techniques to reveal tumour heterogeneity from standard medical images. This new study, led by Professor Sala, involved a small group of patients with advanced ovarian cancer who were due to have ultrasound-guided biopsies prior to starting chemotherapy.
For the study, the patients first had a standard-of-care CT scan. A CT scanner uses x-rays and computing to create a 3D image of the tumour from multiple image ‘slices’ through the body.
The researchers then used a process called radiomics – using high-powered computing methods to analyse and extract additional information from the data-rich images created by the CT scanner – to identify and map distinct areas and features of the tumour. The tumour map was then superimposed on the ultrasound image of the tumour and the combined image used to guide the biopsy procedure.
By taking targeted biopsies using this method, the research team reported that the diversity of cancer cells within the tumour was successfully captured.
Co-first author Dr Lucian Beer, from the Department of Radiology and CRUK Cambridge Centre Ovarian Cancer Programme, said of the results: “Our study is a step forward to non-invasively unravel tumour heterogeneity by using standard-of-care CT-based radiomic tumour habitats for ultrasound-guided targeted biopsies.”
Co-first author Paula Martin-Gonzalez, from the Cancer Research UK Cambridge Institute and CRUK Cambridge Centre Ovarian Cancer Programme, added: “We will now be applying this method in a larger clinical study.”
Professor Sala said: “This study provides an important milestone towards precision tissue sampling. We are truly pushing the boundaries in translating cutting edge research to routine clinical care.”
Fiona Barve (56) is a science teacher who lives near Cambridge. She was diagnosed with ovarian cancer in 2017 after visiting her doctor with abdominal pain. She was diagnosed with stage 4 ovarian cancer and immediately underwent surgery and a course of chemotherapy. Since March 2019 she has been cancer free and is now back to teaching three days a week.
“I was diagnosed at a late stage and I was fortunate my surgery, which I received within four weeks of being diagnosed, and chemotherapy worked for me. I feel lucky to be around,” said Barve.
“When you are first undergoing the diagnosis of cancer, you feel as if you are on a conveyor belt, every part of the journey being extremely stressful. This new enhanced technique will reduce the need for several procedures and allow patients more time to adjust to their circumstances. It will enable more accurate diagnosis with less invasion of the body and mind. This can only be seen as positive progress.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Data at AACR Demonstrate Growing Clinical Utility…on April 10, 2021 at 7:00 am
Phase 2 trial of Amgen’s investigational KRASG12C inhibitor, sotorasib, demonstrated comparable efficacy between patients identified as KRASG12C positive using Guardant360 CDx liquid biopsy or tissue ...
- Dr. Polak on Evaluation of Cancer Genomes in Ghana Utilizing Liquid Biopsieson April 10, 2021 at 6:56 am
discusses research that evaluated cancer genomes in Ghana through the use of liquid biopsies. Findings presented during the 2021 Virtual AACR Annual Meeting identified a specific copy number ...
- Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancerson April 10, 2021 at 5:35 am
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at the AACR Virtual Annual Meeting I, April 10-15, 2021, highlighting the ...
- Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual ...on April 10, 2021 at 5:33 am
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at . AACR Virtual Annual Meeting 2021. Inivata’s RaDaR ® MRD assay performed with exceptionally high sens ...
- Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021on April 10, 2021 at 5:30 am
Research Triangle Park, NC, USA and Cambridge, UK, 10 April 2021 -- Inivata, a leader in liquid biopsy, today unveils new data at the American Association for Cancer Research (AACR) Virtual Annual ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Precision tissue sampling
- Measuring ctDNA With ddPCR May Help Drive Precision Medicine in Pancreatic Canceron April 9, 2021 at 1:51 pm
A recent review took a look at the promise of measuring circulating tumor DNA (ctDNA) with digital-droplet PCR (ddPCR) in pancreatic ductal adenocarcinoma (PDAC) as the landscape of this cancer ...
- global market for regenerative medicines is predicted to grow at a CAGR of 13.99% over the forecast period of 2020-2030on April 9, 2021 at 3:10 am
Global Regenerative Medicines Market to Reach $87. 03 Billion by 2030. Market Report Coverage - Regenerative Medicines Market Segmentation.New York, April 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com ...
- NanoString Highlights Spatial Biology Research from the 2021 American Association of Cancer Research (AACR) Conferenceon April 8, 2021 at 7:00 am
Under the program, customers can submit tissue samples to NanoString for analysis using the spatial profiling platforms ... simultaneously with high sensitivity and precision, facilitating a wide ...
- Making the choice between bioelectrical impedance measures for body hydration status assessmenton April 8, 2021 at 3:29 am
Bioimpedance analysis (BIA) has been suggested as an alternative to ... BIA can provide estimates of body compartments by measuring the resistance and reactance of biological tissue at various low- ...
- Cancer Tissue Diagnostic Equipment Demand Rising in Response to Increasing Cancer Cases: Future market Insights Studyon April 6, 2021 at 7:14 am
It is driven by the increasing investment in cancer research activities to discover high precision biomarkers ... www.futuremarketinsights.com/reports/sample/rep-gb-4191 Prominent players featured in ...